Whitehawk Therapeutics appoints former Incyte executive Vijay Iyengar to board
WHWK•Board appointment
Whitehawk Therapeutics appointed Vijay Iyengar to its board, effective Sept. 9, 2026.
Iyengar previously held senior leadership roles at Incyte, supporting five brand launches across eight indications and expansion into more than 20 countries.
He also held senior oncology leadership roles at Novartis, earlier serving as an engagement manager at McKinsey’s healthcare practice.
